(Q35949518)
Statements
Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma (English)
C M M Prado
T Bekaii-Saab
L A Doyle
S Shrestha
S Ghosh
1 reference
1 reference